MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma
Metrics: PDF 1239 views | HTML 1780 views | ?
Jing Zhang1, Lei Guo1, Xiuyun Liu1, Wenbin Li1, Jianming Ying1
1Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Jianming Ying, email: email@example.com
Keywords: gastric cancer, MET overexpression, MET gene amplification, biomarker, immunohistochemistry
Received: October 21, 2016 Accepted: December 13, 2016 Published: December 30, 2016
This study was conducted to investigate the expression of MET in Chinese gastric adenocarcinoma cohort, the correlation between MET overexpression and clinical pathological features, HER2 expression and MET gene amplification. A total of 816 gastric adenocarcinoma patients were included and MET and HER2 immunohistochemical (IHC) staining were performed. IHC and dual-color silver in situ hybridization analysis were performed in the tissue microarrays, constructed from the 240 patients who were randomly selected. MET overexpression (IHC 3+) was observed in 6.0% (49/816) of the cohort. MET overexpression rate was higher in patients with poor prognostic factors, such as clinical stages III/IV (p =0.012) and pathologic stages T3/T4 (p =0.027). The HER2 overexpression (IHC 3+) rate was 8.8% (72/816) and MET overexpression rate was higher in HER2 positive patients (9.7%, 7/72). A high concordance rate (94.6%) between MET overexpression and gene amplification was demonstrated. Therefore, MET overexpression could serve as a prognostic biomarker and a potential therapeutic target for gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.